These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 39141281)
1. The Broader Effects of Delayed Progression to End-Stage Kidney Disease: Delaying the Inevitable or a Meaningful Change? Correa-Rotter R; Wheeler DC; McEwan P Adv Ther; 2024 Oct; 41(10):3739-3748. PubMed ID: 39141281 [TBL] [Abstract][Full Text] [Related]
2. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease. Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K Diabetes Obes Metab; 2022 Nov; 24(11):2138-2147. PubMed ID: 35676798 [TBL] [Abstract][Full Text] [Related]
3. Comparison of health literacy profile of patients with end-stage kidney disease on dialysis versus non-dialysis chronic kidney disease and the influencing factors: a cross-sectional study. Murali K; Mullan J; Roodenrys S; Lonergan M BMJ Open; 2020 Oct; 10(10):e041404. PubMed ID: 33122326 [TBL] [Abstract][Full Text] [Related]
4. Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis. McEwan P; Hafner M; Jha V; Correa-Rotter R; Chernin G; De Nicola L; Villanueva R; Wheeler DC; Barone S; Nolan S; Garcia Sanchez JJ J Med Econ; 2023; 26(1):1407-1416. PubMed ID: 37807895 [TBL] [Abstract][Full Text] [Related]
5. Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease? Siddiqui R; Obi Y; Dossabhoy NR; Shafi T Curr Hypertens Rep; 2024 Dec; 26(12):463-474. PubMed ID: 38913113 [TBL] [Abstract][Full Text] [Related]
6. Low protein diets for non-diabetic adults with chronic kidney disease. Hahn D; Hodson EM; Fouque D Cochrane Database Syst Rev; 2018 Oct; 10(10):CD001892. PubMed ID: 30284724 [TBL] [Abstract][Full Text] [Related]
7. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. Giorgino F; Vora J; Fenici P; Solini A Cardiovasc Diabetol; 2020 Nov; 19(1):196. PubMed ID: 33222693 [TBL] [Abstract][Full Text] [Related]
8. Low protein diets for non-diabetic adults with chronic kidney disease. Hahn D; Hodson EM; Fouque D Cochrane Database Syst Rev; 2020 Oct; 10(10):CD001892. PubMed ID: 33118160 [TBL] [Abstract][Full Text] [Related]
9. Chronic kidney disease in type 2 diabetes: The size of the problem, addressing residual renal risk and what we have learned from the CREDENCE trial. Chaudhry K; Karalliedde J Diabetes Obes Metab; 2024 Oct; 26 Suppl 5():25-34. PubMed ID: 39044385 [TBL] [Abstract][Full Text] [Related]
10. Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study. Koye DN; Magliano DJ; Reid CM; Jepson C; Feldman HI; Herman WH; Shaw JE Am J Kidney Dis; 2018 Nov; 72(5):653-661. PubMed ID: 29784612 [TBL] [Abstract][Full Text] [Related]
11. Oral adsorbents for preventing or delaying the progression of chronic kidney disease. Wu HM; Sun HJ; Wang F; Yang M; Dong BR; Liu GJ Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD007861. PubMed ID: 25317905 [TBL] [Abstract][Full Text] [Related]
12. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape. Mende CW Adv Ther; 2022 Jan; 39(1):148-164. PubMed ID: 34846711 [TBL] [Abstract][Full Text] [Related]
13. Projection of the health and economic impacts of Chronic kidney disease in the Chilean population. Walbaum M; Scholes S; Rojas R; Mindell JS; Pizzo E PLoS One; 2021; 16(9):e0256680. PubMed ID: 34495980 [TBL] [Abstract][Full Text] [Related]
14. Early Identification and Management of Chronic Kidney Disease: A Narrative Review of the Crucial Role of Primary Care Practitioners. Kushner P; Khunti K; Cebrián A; Deed G Adv Ther; 2024 Oct; 41(10):3757-3770. PubMed ID: 39162984 [TBL] [Abstract][Full Text] [Related]
15. Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Cao H; Rao X; Jia J; Yan T; Li D Acta Diabetol; 2023 Mar; 60(3):325-335. PubMed ID: 36316605 [TBL] [Abstract][Full Text] [Related]
16. Atherosclerotic vascular disease is more prevalent among black ESKD patients on long-term CAPD in South Africa. Oguntola SO; Hassan MO; Duarte R; Vachiat A; Manga P; Naicker S BMC Nephrol; 2019 Oct; 20(1):399. PubMed ID: 31666030 [TBL] [Abstract][Full Text] [Related]
18. Adolescents and Young Adults with Chronic or End-Stage Kidney Disease. Ferris ME; Miles JA; Seamon ML Blood Purif; 2016; 41(1-3):205-10. PubMed ID: 26765837 [TBL] [Abstract][Full Text] [Related]
19. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878 [TBL] [Abstract][Full Text] [Related]
20. Urologic care and progression to end-stage kidney disease: a Chronic Kidney Disease in Children (CKiD) nested case-control study. Chu DI; Abraham AG; Tasian GE; Denburg MR; Ross ME; Zderic SA; Furth SL J Pediatr Urol; 2019 May; 15(3):266.e1-266.e7. PubMed ID: 30962011 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]